Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab Phase 3 in Palmoplantar Pustulosis
NCT02641730Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in palmoplantar pustulosis (PPP), sponsored by Janssen Pharmaceutical. Started Dec 2015; status: completed.
02
Drugs
guselkumab
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT02641730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641730.